Besides Angptl4, Angptl3 is another inhibitor of LPL, and loss-of-function mutations of Angptl3 are correlated with lower levels of TGs and cholesterol, and Angptl3 genetic deficiency is protective against ASCVD; thus, pharmacologic inhibition of Angptl3 is under current investigation as promising lipid-lowering therapy [97,98,99]. The gene discussed is ANGPTL3; the disease is atherosclerosis.